Gary Sender, Chief Financial Officer at Nabriva Therapeutics plc (NBRV), bought 2,000 shares at $4.57 ($9K) on 2018-05-23, disclosed to the SEC on 2018-05-23.
Open-market purchase of $9k NBRV by Chief Financial Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Something here stands out, but not much.
| Filing → |
| NBRV | BUY | 2017-09-26 | $16K | — | Filing → |